These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 22789772

  • 1. [Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder].
    Sicras-Mainar A, Mauriño J, Cordero L, Blanca-Tamayo M, Navarro-Artieda R.
    Aten Primaria; 2012 Nov; 44(11):667-75. PubMed ID: 22789772
    [Abstract] [Full Text] [Related]

  • 2. [Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting].
    Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, Salvatella-Pasant J, Navarro-Artieda R.
    Gac Sanit; 2010 Nov; 24(1):13-9. PubMed ID: 19646795
    [Abstract] [Full Text] [Related]

  • 3. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C, Becker RV, Mucha L, Lorenz BH, Eaddy MT, Ogbonnaya AO.
    Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
    [Abstract] [Full Text] [Related]

  • 4. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V, Patel H, Kurlander JL, Essoi B, Yang J, Mahableshwarkar AR, Samp JC, Akhras KS.
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [Abstract] [Full Text] [Related]

  • 5. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J, Joish V.
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [Abstract] [Full Text] [Related]

  • 6. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
    Sicras-Mainar A, Navarro-Artieda R, Blanca-Tamayo M, Gimeno-de la Fuente V, Salvatella-Pasant J.
    Curr Med Res Opin; 2010 Dec; 26(12):2757-64. PubMed ID: 21034375
    [Abstract] [Full Text] [Related]

  • 7. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.
    Shrestha SS, Zhang P, Li R, Thompson TJ, Chapman DP, Barker L.
    Diabetes Res Clin Pract; 2013 Apr; 100(1):102-10. PubMed ID: 23490596
    [Abstract] [Full Text] [Related]

  • 8. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G, Zhang L, DiBernardo A, Wang G, Sheehan JJ, Lee K, Reutfors J, Zhang Q.
    PLoS One; 2020 Apr; 15(9):e0238843. PubMed ID: 32915863
    [Abstract] [Full Text] [Related]

  • 9. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
    Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB.
    CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
    [Abstract] [Full Text] [Related]

  • 10. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T, Ming T, Waller J, Bailey T, Rajkovic-Hooley O, Middleton-Dalby C, Le HH, Zhang Q, McCrone P, Taylor D.
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [Abstract] [Full Text] [Related]

  • 11. [Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension].
    Sicras Mainar A, Galera Llorca J, Muñoz Ortí G, Navarro Artieda R.
    Med Clin (Barc); 2011 Feb 26; 136(5):183-91. PubMed ID: 21106209
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients.
    Xiao L, Zhou JJ, Feng Y, Zhu XQ, Wu WY, Hu YD, Niu YJ, Hu J, Wang XY, Gao CG, Zhang N, Fang YR, Liu TB, Jia FJ, Feng L, Wang G.
    Asian J Psychiatr; 2020 Jan 26; 47():101843. PubMed ID: 31731143
    [Abstract] [Full Text] [Related]

  • 18. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
    Cui Z, Faries DE, Zhao Y, Novick D, Liu X.
    J Med Econ; 2011 Jan 26; 14(5):662-72. PubMed ID: 21892857
    [Abstract] [Full Text] [Related]

  • 19. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008 Jan 26; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.